Following the recent media coverage of the Declaration, co-signed by Destiny Pharma, calling on governments to work with them to develop new and alternative market structures that provide more dependable and sustainable market models for antibiotics, and to commit the funds needed to implement them, interviews with Dr Bill Love, CEO of Destiny Pharma have appeared in a number of recent publications. Interviewed in SCRIP Intelligence, the leading source of news and strategic analysis for the global pharmaceutical industry, Dr Love outlined the current clinical development status of XF-73 (exeporfinium chloride), Destiny Pharma’s lead product, in the US. With the completion in the coming weeks of a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), studying Staphylococcus aureus (SA) decolonization (i.e. the clearance of SA from the nostrils of carriers) as well as safety and tolerability, and the recent Qualified Infectious Disease Product Designation Granted to XF-73 by the FDA for Novel Antibacterial Product In Development for Prevention of Post-Surgical Staphylococcal Infections, the article noted that Destiny Pharma has “placed itself firmly on the radar in the US”. In a further interview with EP Vantage, Dr Love detailed the unique properties that XF-73 has which make it ideally placed to become the drug of choice for the prevention of post-surgical Staphylococcal infections once it is approved. Dr Love also outlined the need for new antibacterial drugs to combat the issue of resistance, and how government incentives such as the US GAIN (Generating Antibiotic Incentives Now) Actare stimulating the research focus on developing new antibacterial drugs. For further information about Destiny Pharma or to arrange an interview with Dr Love, please contact: email@example.com.